Pericarditis Market

Key Highlights

• The Pericarditis market is expected to grow significantly by 2036.
• The U.S. pericarditis market is transitioning from conventional anti-inflammatory management toward targeted, steroid-sparing and more convenient therapies, with rilonacept establishing the commercial benchmark while CardiolRx, KPL-387 and VTX2735 represent the most visible U.S.-relevant late-stage/emerging approaches.
• The major competitive dimensions are likely to include recurrence prevention, speed of inflammatory control, immunosuppression/infection risk, route of administration, dosing frequency and duration of treatment.
• Approximately 5% of emergency-department evaluations for chest pain are attributed to pericarditis in ACC guidance.
• Acute pericarditis is reported more frequently in men; recurrent disease has a comparatively greater representation among women.
• Key companies active in the market include Kiniksa Pharmaceuticals; Cardiol Therapeutics; Ventyx Biosciences/Zomagen Biosciences; R-Pharm International; Regeneron Pharmaceuticals.

DelveInsight's "Pericarditis Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Pericarditis, historical and forecasted epidemiology as well as the Pericarditis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pericarditis market report provides current treatment practices, emerging drugs, Pericarditis market share of the individual therapies, current and forecasted Pericarditis market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Pericarditis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pericarditis market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2022-2036

Key Factors Driving Market Growth

• High recurrence burden: Recurrent pericarditis can persist for years, creating a continuing need for anti-inflammatory treatment and disease-management strategies rather than one-time therapy. Kiniksa reports that approximately one-third of patients with multiple recurrences continue to experience disease at five years.
• Unmet need beyond conventional therapy: NSAIDs and colchicine remain foundational treatments, but patients with recurrent, colchicine-resistant or steroid-dependent disease require additional options, supporting demand for targeted therapies.
• Validation of IL-1 biology: Clinical experience with IL-1 inhibition has established inflammatory signaling as an important therapeutic target, encouraging development of next-generation IL-1 and inflammasome-directed medicines.
• Demand for convenient dosing: Existing rilonacept treatment requires weekly subcutaneous administration. Emerging programs are pursuing oral, monthly or potentially quarterly dosing to reduce treatment burden and potentially broaden patient adoption.
• Expansion of targeted therapies: The pipeline is moving beyond direct IL-1 blockade toward NLRP3 inhibition and other upstream inflammatory mechanisms, creating opportunities for differentiated treatment approaches.

Pericarditis Disease Understanding and Treatment Algorithm

Pericarditis is an inflammatory disorder of the pericardium, the two-layered sac surrounding the heart. It may occur as an isolated/idiopathic condition, after viral or bacterial infection, following myocardial infarction or cardiac surgery, or in association with autoimmune, inflammatory, malignant, metabolic, or systemic diseases. The condition commonly presents with sharp, pleuritic chest pain that may improve when sitting forward, along with dyspnea, fever, fatigue and a pericardial friction rub. Pericarditis may be acute, incessant, recurrent, or chronic. Recurrent pericarditis is particularly important commercially because patients can experience repeated inflammatory flares over several years and may require prolonged anti-inflammatory treatment.

Pericarditis Diagnosis

Diagnosis is primarily clinical and is supported by electrocardiography, inflammatory biomarkers and cardiac imaging. The diagnosis of acute pericarditis generally relies on characteristic clinical findings such as typical chest pain, a pericardial friction rub, widespread ST-segment elevation/PR-segment depression on ECG, and new or worsening pericardial effusion; echocardiography is particularly useful for identifying effusion and assessing hemodynamic consequences. CRP/ESR, troponin testing and other laboratory investigations help characterize inflammation and identify myocardial involvement or an underlying cause. Echocardiography is generally the first-line imaging modality, while cardiac MRI can provide additional evidence of active pericardial inflammation and help characterize difficult or recurrent cases. CT may be useful for assessing pericardial thickening, calcification or alternative diagnoses.

Pericarditis Treatment

Treatment depends on the etiology, inflammatory activity, severity and whether the disease is an initial or recurrent episode. NSAIDs or aspirin plus colchicine remain the principal first-line approach for acute inflammatory pericarditis, with colchicine generally continued for several months to reduce recurrence. Corticosteroids can be used in selected patients, particularly when NSAIDs/colchicine are contraindicated or when an autoimmune indication exists, but prolonged steroid exposure is generally avoided because of toxicity and potential recurrence concerns. For recurrent or colchicine-resistant pericarditis, inhibition of the IL-1 pathway has become an important therapeutic strategy. Rilonacept is FDA approved for recurrent pericarditis, while anakinra is used off-label in appropriate patients. Severe pericardial effusion with tamponade requires urgent drainage, while constrictive disease that is refractory to medical management may require pericardiectomy.

Pericarditis Epidemiology 

The Pericarditis epidemiology section provides insights about the historical and current Pericarditis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pericarditis market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pericarditis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

Pericarditis Drug Chapters

The drug chapter segment of the Pericarditis report encloses the detailed analysis of Pericarditis marketed drugs and late-stage (Phase-III and Phase-II) Pericarditis pipeline drugs. It also helps to understand the Pericarditis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Pericarditis Emerging Drugs

KPL-387: Kiniksa Pharmaceuticals

KPL-387 is an investigational fully human monoclonal antibody targeting IL-1 receptor 1 (IL-1R1), thereby inhibiting signaling from both IL-1α and IL-1β. Its principal differentiation from ARCALYST is the potential for once-monthly subcutaneous administration in a liquid formulation rather than weekly dosing. Kiniksa began the Phase 2 dose-focusing portion of its Phase 2/3 program in July 2025, and the FDA granted Orphan Drug Designation in October 2025. In July 2026, Kiniksa reported that the 300-mg monthly dose produced rapid and sustained reductions in pain and inflammation, with treatment response occurring at a median of 4 days and CRP normalization at 8 days; the pivotal Phase 3 PASTORALE study was enrolling patients.

CardiolRx: Cardiol Therapeutics

CardiolRx is an oral pharmaceutical formulation of cannabidiol (CBD) being developed as a non-immunosuppressive anti-inflammatory therapy for recurrent pericarditis. The drug is designed to offer an oral alternative to injectable IL-1 inhibitors and is being studied particularly in patients transitioning away from IL-1 blockade. Cardiol initiated its pivotal Phase 3 MAVERIC trial in recurrent pericarditis in 2025 following FDA alignment on the trial design. By January 2026, more than 50% of patients had been enrolled, with more than 15 U.S. cardiovascular centers actively recruiting; the Phase 3 program was subsequently expanded, and Cardiol reported in May 2026 that enrollment had surpassed 75%.

Recent Developments in the Pericarditis Market

• In July 2026, Kiniksa reported positive interim Phase 2 data for KPL-387, showing rapid and sustained reductions in pain and inflammation with the 300-mg monthly subcutaneous regimen. The company was enrolling patients in the pivotal Phase 3 PASTORALE study.
• In July 2026, CardiolRx Phase 2 recurrent-pericarditis results were published in the Journal of the American Heart Association, while the pivotal Phase 3 MAVERIC study continued recruiting U.S. patients.
• In April 2026, Kiniksa announced plans to initiate the pivotal Phase 3 study of KPL-387 by the end of 2026, following Phase 2 development.
• In January 2026, Cardiol Therapeutics reported that MAVERIC had exceeded 50% enrollment, with more than 15 leading U.S. cardiovascular centers actively recruiting.

Pericarditis Market Outlook

The Pericarditis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pericarditis market trends by analyzing the impact of current Pericarditis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Pericarditis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pericarditis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pericarditis market in 7MM is expected to witness a major change in the study period 2022-2036.

Pericarditis Drugs Uptake

This section focuses on the rate of uptake of the potential Pericarditis drugs recently launched in the Pericarditis market or expected to get launched in the market during the study period 2022-2036. The analysis covers Pericarditis market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Pericarditis Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Pericarditis market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pericarditis Pipeline Development Activities

The Pericarditis report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Pericarditis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Pericarditis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Pericarditis emerging therapies.

Reimbursement Scenario in Pericarditis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Pericarditis market trends, we take KOLs and SMEs ' opinion working in the Pericarditis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pericarditis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Pericarditis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Pericarditis Market Report

• The Pericarditis Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along Pericarditis Treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Pericarditis Treatment landscape.
• A detailed review of the Pericarditis Therapeutics Market, historical and forecasted Pericarditis Treatment Market Size, Pericarditis Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Pericarditis Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Pericarditis Drugs Market.

Pericarditis Market Report Insights

• Pericarditis Patient Population Forecast
• Pericarditis Therapeutics Market Size
• Pericarditis Pipeline Drugs Analysis
• Pericarditis Market Size and Trends
• Pericarditis Therapeutics Market Opportunity (Current and Forecasted)

Pericarditis Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Pericarditis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Pericarditis Treatment Addressable Market (TAM)
• Pericarditis Competitive Landscape
• Pericarditis Major Companies Insights
• Pericarditis Price Trends and Analogue Assessment
• Pericarditis Therapies Drug Adoption/Uptake
• Pericarditis Therapies Peak Patient Share Analysis

Pericarditis Market Report Assessment

• Pericarditis Current Treatment Practices
• Pericarditis Unmet Needs
• Pericarditis Clinical Development Analysis
• Pericarditis Emerging Drugs Product Profiles
• Pericarditis Market Attractiveness
• Pericarditis Qualitative Analysis (SWOT and Attribute analysis)

Key Questions Answered in the Pericarditis Treatment Market Report

Pericarditis Therapeutics Market Insights

• What was the Pericarditis Treatment Market Size, the Pericarditis Market Size by therapies, Pericarditis Drugs Market Share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Pericarditis?
• What are the disease risks, burdens, and unmet needs of Pericarditis? 
• What will be the growth opportunities across the 7MM concerning the patient population with Pericarditis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Pericarditis? What are the current guidelines for treating Pericarditis in the US, Europe, and Japan?

Reasons to Buy the Pericarditis Therapeutics Market Report

• The Pericarditis Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Pericarditis Drugs Market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Pericarditis Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Pericarditis Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Pericarditis Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Pericarditis Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.